Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3

Pulm Pharmacol Ther. 2022 Feb:72:102097. doi: 10.1016/j.pupt.2021.102097. Epub 2021 Nov 17.

Authors

Swarupa Kulkarni¹, Birk Poller², Anton Drollmann³, Bharti Shah⁴, Cathy Gray⁴, Erin Greco³, Gholamreza Rahmanzadeh², Imad Hanna⁴, H Markus Weiss²

Affiliations

¹ Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. Electronic address: [email protected].
² Novartis Institutes for Biomedical Research, Basel, Switzerland.
³ Novartis Pharma, AG, Basel, Switzerland.
⁴ Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.

PMID: 34800680
DOI: 10.1016/j.pupt.2021.102097

No abstract available

Keywords: Drug-drug interaction; Fevipiprant; Penicillin G; Pharmacokinetics; QAW039; Zidovudine.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Glucuronides*
Indoleacetic Acids
Penicillin G
Pyridines
Receptors, Prostaglandin
Zidovudine*

Substances

Glucuronides
Indoleacetic Acids
Pyridines
Receptors, Prostaglandin
fevipiprant
Zidovudine
Penicillin G